Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection-Reference-Cited by-同舟云学术

Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection

Published:2020-06-27 Issue:10 Volume:34 Page:2704-2707
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Wang Ying,Liu Yang,Tan Xu,Pan Bin^ORCID,Ge Jian,Qi Kunming,Cheng Hai,Cao Jiang,Shi Ming,Yan Zhiling,Qiao Jianlin,Jing Guangjun,Wang Xue,Sang Wei,Xia Ruixiang,Zhang Xi,Li Zhenyu,Gale Robert Peter,Zheng Junnian^ORCID,Zhu Feng^ORCID,Xu Kailin^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0936-4.pdf

Reference9 articles.

1. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.

2. Tsukune Y, Sasaki M, Odajima T, Sunami K, Takei T, Moriuchi Y. et al.Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan. Blood Cancer J. 2017;7:631.

3. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32:3736–43.

4. Cheng CL, Huang SC, Chen JH, Wei CH, Fang WQ, Su TH, et al. Hepatitis B surface antigen positivity is an independent unfavorable prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Oncologist. 2020. [Epub ahead of print].

5. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution and diversity of the hepatitis B virus genome: Clinical implications;Virology;2024-10

2. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

3. Post-Chimeric Antigen Receptor T-Cell Therapy Hepatitis B Virus Reactivation After 23 Months of Entecavir Prophylaxis;ACG Case Reports Journal;2024-09

4. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis;Liver International;2024-08-29

5. CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B related cirrhosis;2024-08-10